
About SkinJect
SkinJect is a Healthcare company based in Pittsburgh (United States) founded in 2015. Dissolvable microneedle patches for non-melanoma skin cancer treatment are developed. It operates on a HealthTech model. SkinJect has raised $3.4 million across 4 funding rounds from investors including Velocity Fund Partners. Its chief executive, as recorded, is James M Nolan. SkinJect offers products and services including SkinJect Patch. Its focus areas include Medical Devices and Dermatological Devices. Its competitors include Enable Injections, Aura Biosciences and Micron Biomedical; 3 of its 3 listed competitors have raised funding.
Company details
SkinJect is engaged in the development of innovative solutions for treating basal cell and squamous cell skin cancer. A dissolvable microneedle patch is being created as a less invasive and less painful treatment option. The company operates in the dermatology sector, addressing an unmet clinical need with a focus on reducing recurrence rates. Efforts are directed toward advancing technologies and securing regulatory clearances for commercialization in a competitive market.
- Headquarters Pittsburgh, United States
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website skinjectpatch.com
- Social LinkedIn X
- Total Equity Funding$3.4M (USD)
in 4 rounds
- Latest Funding Round$895.09K (USD), Series A
Jul 2021
- Investors
Products & Services of SkinJect
SkinJect offers a comprehensive portfolio of products and services, including SkinJect Patch.
A microneedle patch developed for skin cancer treatment.
Funding Insights of SkinJect
SkinJect has successfully raised a total of $3.4M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $895.09 thousand completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.4M
- Total Rounds 4
- Last Round Series A β $895,091
- First Round $500,000
(Dec 2015)
- Investors Count 1
All 4 funding rounds of SkinJect with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2021 | $895,091 | Series A | β | β | β |
| May 2019 | $2.5M | Series A | β | β | β |
| May 2016 | Seed | β | β | ||
| Dec 2015 | $500,000 | Debt – Conventional | β | β | β |
1 investors in total: 1 institutional.
Investors in SkinJect
SkinJect has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Velocity Fund Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are directed toward USA-based companies. | 2016 | velocityfp.com | Pittsburgh, United States |
Investor details for SkinJect
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SkinJect
4 people are tracked at SkinJect (4 in leadership).
| Name | Role | Group |
|---|---|---|
James M Nolan | CEO | Leadership |
Michael J. Fare | President & COO | Leadership |
Joseph Donnelly | CFO | Leadership |
O. Burak Ozdoganlar | Chief Technical Advisor | Leadership |
Complete people profiles for SkinJect
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of SkinJect
3 dated milestones of SkinJect across 6 years, from founding to its latest funding, stage changes and deals.
- Founded SkinJect is founded.
- Funding First funding round of $500K.
- Funding Latest funding round, Series A, of $895K.
Competitors of SkinJect
SkinJect has 3 listed competitors in our database, 3 of them funded. They include Enable Injections, Aura Biosciences and Micron Biomedical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| enableinjections.com | 2010 | Cincinnati, United States | $304.27M | 185 | Provider of a wearable drug delivery solution | |
| aurabiosciences.com | 2007 | Cambridge, United States | $215.46M | 21 | Therapies are developed to target and destroy cancer cells selectively. | |
| micronbiomedical.com | 2014 | Atlanta, United States | $33M | 11 | Microneedle patches are developed for vaccine and drug delivery. |
Detailed competitors of SkinJect
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as SkinJect (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Skinject
Complete news archive for SkinJect
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SkinJect
SkinJect was founded in 2015.
SkinJect is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
James M Nolan is the CEO of SkinJect, as recorded in our data.
SkinJect is a funded company, having raised a total of $3.4M across 4 funding rounds to date. The company's 1st funding round was a Debt β Conventional of $500K, raised on Dec 2015.
SkinJect is engaged in the development of innovative solutions for treating basal cell and squamous cell skin cancer. A dissolvable microneedle patch is being created as a less invasive and less painful treatment option. The company operates in the dermatology sector, addressing an unmet clinical need with a focus on reducing recurrence rates. Efforts are directed toward advancing technologies and securing regulatory clearances for commercialization in a competitive market.
SkinJect's top competitors include Enable Injections, Aura Biosciences and Micron Biomedical.
SkinJect offers SkinJect Patch.
SkinJect has 1 investor. Key investors include Velocity Fund Partners.
